Aethlon Medical re-establishes bioterror countermeasures program

Officials with Aethlon Medical, Inc., recently announced that they have re-established their efforts to advance their Aethlon Hemopurifier within U.S. government programs to provide countermeasures against bioterror threats.

The Aethlon Hemopurifier is the first medical device to selectively target the removal of infectious viruses from the entire circulatory system.

Jim Joyce, Aethlon's chairman and CEO, said he believes the Hemopurifier represents the most advanced and perhaps the only true broad spectrum countermeasure against viral threats most likely to be weaponized against civilian and military populations.

Joyce said that his company’s ability target multiple bioterror threats has become a focal point of the U.S. Health and Human Services Department. Joyce said dual-use therapies that also have commercial applications against established disease conditions like hepatitis-C virus and cancer are no longer precluded from consideration to be supported by government programs.

“Revamped government policies expand the opportunity for our Hemopurifier in the United States and improve our potential access to non-dilutive capital resources, which are not capped by the public market value of our organization,” Joyce said. “We now plan to update an investigational device exemption already submitted to the FDA, which if approved, would allow us to collect further clinical data that potentially could contribute to other infectious disease and cancer studies we hope to initiate in the United States.”

Joyce said that the Obama administration recently announced that programs intended to prepare the country for biological weapons attacks would be overhauled with a focus toward decreasing the length of time it takes to produce new medical countermeasures.

Additionally, funding will be directed to the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority to turn scientific breakthroughs into medical countermeasures.

Joyce said the FDA has indicated that it will take steps to eliminate obstacles that could slow the pace of the countermeasure review process.